A Study of LY3435151 in Participants With Solid Tumors

• Status: Terminated
• Trial end date: 2020-03-05
• Target enrollment: 0
• Participant gender: All

Summary

The reason for this study is to see if the study drug LY3435151 is safe in participants with advanced solid tumors.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Pembrolizumab

Criteria

Inclusion Criteria:

• Participant must have certain types of cancer, which your study doctor will discuss with you

• Participant must have stopped other forms of treatment for cancer, which your study doctor will discuss with you

• Participant must be able and willing to provide a sample of your tumor before beginning treatment and once while on treatment. For certain tumor types, the outcome of the biopsy may exclude you from the study treatment (for Phase 1b)

• Participant must agree to use birth control

• Participant must have progressed through or are intolerant to therapies with known clinical benefit, which your study doctor will discuss with you

Exclusion Criteria:

• Participant must not have a history of tuberculosis, uncontrolled HIV or uncontrolled hepatitis B or C virus infection

• Participant must not have an autoimmune disease, which your study doctor will discuss with you

• Participant must not use corticosteroids, which your study doctor will discuss with you

• Participant must not have heart disease, Crohn's disease or brain cancer

• Participant must not be pregnant or breastfeeding